CRMD CorMedix Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * David Matthew T	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Interim CEO and CFO
(Last)          (First)          (Middle) C/O CORMEDIX INC. 300 CONNELL DRIVE, SUITE 4200	3. Date of Earliest Transaction (MM/DD/YYYY) 12/6/2021
(Street) BERKELEY HEIGHTS, NJ 07922 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/6/2021		P		1000.0000	A	$4.5000	3150.0000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$5.5600							(3)	11/1/2031	Common Stock	125000.0000		125000.0000	D
Stock Option (Right to Buy Common Stock)	$8.3200							(2)	1/11/2031	Common Stock	80000.0000		80000.0000	D
Stock Option (Right to Buy Common Stock)	$5.6300							(1)	5/11/2030	Common Stock	125000.0000		125000.0000	D
Stock Option (Right to Buy Common Stock)	$4.0800							(1)	5/11/2030	Common Stock	125000.0000		125000.0000	D

Explanation of Responses:
(1)	These options were granted on 05/11/2020. 83,000 of these options vest annually over four years in four equal installments beginning 05/11/2021, subject to continued employment, and 42,000 of these options vest based on achievement of certain performance milestones, subject to continued employment through the applicable vesting date.
(2)	These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones.
(3)	These options were granted on 11/1/2021. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
David Matthew T C/O CORMEDIX INC. 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS, NJ 07922			Interim CEO and CFO

Signatures
/s/ Matthew T. David		12/7/2021
**Signature of Reporting Person		Date